Biosimilar Filgrastim Treatment Patterns And Relative Dose Intensity (Rdi) Maintenance In Patients Receiving Chemotherapy (Ct) For The Treatment Of Solid Tumor (St) Or Lymphoid Malignancies (Lm): A French National Observational Study (The Zohe Study)

e20655 Background: Guidelines recommend granulocyte-colony stimulating factor use to reduce the risk of neutropenic complications in patients receiving CT and to enable delivery of full-dose CT. ZOHe is a French prospective non-interventional longitudinal study describing biosimilar (BS) filgrastim (Zarzio) use in routine practice. Methods: Patients ≥ 18 yo receiving treatment for ST or LM were recruited. This analysis reports BS filgrastim treatment characteristics along with CT in terms of dose, day of initiation, duration and proportion of patients for which CT RDI was conserved (dose maintained in ≥ 85% of CT cycles). Data were collected at BS filgrastim initiation and 3 months after inclusion. Results: 1756 evaluable patients were recruited from June 2013 to April 2014, among whom 1141 (65%) had ST and 615 (35%) had LM. In both cohorts, a median BS filgrastim dose of 30 MIU/day was used in the vast majority of cycles. BS filgrastim was started on average 4.3 ± 2.2 days and 6.5 ± 2.2 days after CT for...